Nothing drives down a drug’s price like competition. According the U.S. Food and Drug Administration (FDA), a drug’s ...

We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look ...

Dr. Harry Wasvary is Joshi’s doctor and the Chief of Colorectal Surgery at Corewell Health William Beaumont University ...

MUSC Hollings Cancer Center, US, has enrolled the first subject in the trial of ficerafusp alfa to treat individuals with HPV ...

Vicero, Inc., a preclinical-stage biopharmaceutical company developing next-generation VINCOBODIES for immune-mediated diseases, today announced the appointment of two distinguished oncologists and ...

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial ...

Muzastotug Phase 2 dose expansion in MSS CRC with a 20 mg/kg loading dose regimen shows 33% overall response rate with four confirmed partial responses SAFEbody technology utilized to create masked ...

However, a Stocktwits poll indicates retail traders remain skeptical, with some flagging it as a potential pump-and-dump risk ...

The big biotech signed a 15-year lease for approximately 580,000-square-feet of space in “Kendall Commons,” a development project spearheaded by MIT.

The addition of pembrolizumab to chemoradiotherapy improved survival outcomes for women with high-risk, locally advanced ...

The FDA has granted traditional approval to Keytruda (pembrolizumab) in combination with trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Skin cancer advanced clinical practitioners ensure continuity of care for patients with malignant melanoma and other advanced ...